Estrogen Receptor Beta (ERβ; NR3A2)

This gene encodes a member of the family of estrogen receptors and superfamily of nuclear receptor transcription factors. The gene product contains an N-terminal DNA binding domain and C-terminal ligand binding domain and is localized to the nucleus, cytoplasm, and mitochondria. Upon binding to 17beta-estradiol or related ligands, the encoded protein forms homo- or hetero-dimers that interact with specific DNA sequences to activate transcription. Some isoforms dominantly inhibit the activity of other estrogen receptor family members. Several alternatively spliced transcript variants of this gene have been described, but the full-length nature of some of these variants has not been fully characterized.

[Provided by RefSeq, Jul 2008]

Estrogen Receptor Beta Structure


(From Structure)


(From Aceview)

There are 566 articles specifically referring to this gene in PubMed. Functionally, the gene has been tested for association to diseases (Adenocarcinoma; Atherosclerosis; Biliary Tract Neoplasms; Bipolar Disorder; bone density; Graves' disease; thyroiditis, Hashimoto's; bone mineral density; Breast Neoplasms; Carcinoma, Non-Small-Cell Lung; Cardiomyopathy, dilated; Colonic Neoplasms and 26 others) and proposed to participate in processes (behavioral fear response, brain development, epithelial cell maturation involved in prostate gland development, learning or memory, negative regulation of androgen receptor signaling pathway and 13 others). Proteins are expected to have molecular functions (hormone binding, metal ion binding, sequence-specific DNA binding, transcription factor activity, zinc ion binding) and to localize in various compartments (nucleus, cytoplasm, neuron projection, perikaryon). Putative protein interactors have been described (AKAP13, AKT1, AMPD1ANDDENND2CANDBCAS2, ANKRD35ANDPIAS3, CALM1, CALM3, CCNC, CDK8, DAP3, DDX5 and 57 others). 

(From HuGENavigator)

Over 150 Diseases associated with this receptor. Please see HuGENavigator for more information.

  • Breast Neoplasms 
  • Prostatic Neoplasms 
  • Osteoporosis 
  • Osteoporosis, Postmenopausal 
  • Cardiovascular Diseases 
  • Endometriosis 
  • Colorectal Neoplasms 
  • Infertility, Female 
  • Hypertension 
  • Oligospermia 
  • Parkinson Disease 
  • Polycystic Ovary Syndrome 
  • Alzheimer Disease 
  • Azoospermia 
  • Arthritis, Rheumatoid 
  • Adenocarcinoma 
  • Ovarian Neoplasms 
  • Hypospadias 
  • Obesity 
  • Neoplasm Invasiveness 
  • Lung Neoplasms 
  • Infertility, Male 
  • Scoliosis 
  • Testicular Neoplasms 
  • Coronary Artery Disease 
  • Disease Progression 
  • Endometrial Neoplasms 
  • Fractures, Bone 
  • Gallstones 
  • Hip Fractures 
  • Depressive Disorder, Major 
  • Cryptorchidism 
  • Colonic Neoplasms 
  • Anorexia Nervosa 
  • Abortion, Habitual 
  • Carcinoma 
  • Osteoarthritis 
  • Inflammation 

Assay Kits and Services are available from INDIGO Biosciences.

Kits are offered in different assay formats to accommodate researchers’ needs: 3x 32, 1x 96, and 1x 384 assay formats for screening small numbers of test compounds, as well as custom bulk reagents for HTS applications. Assay systems are all inclusive, providing reporter cells, optimized growth media, media for diluting test compounds, a positive-control agonist, luciferase detection reagent, a white assay plate, a detailed protocol, and a protocol quick guide. All kits are shipped on dry ice.

ERβ Reporter Cells are prepared using INDIGO’s proprietary CryoMite™ process. This cryo-preservation method yields high cell viability post-thaw, and provides the convenience of immediately dispensing healthy, division-competent reporter cells into assay plates. There is no need for intermediate spin-and-wash steps, viability determinations, or cell titer adjustments.

The principle application of this assay product is in the screening of test samples to quantify functional activities, either agonist or antagonist, that they may exert against the estrogen receptor beta. This kit product is an all-inclusive assay system that includes, in addition to ERβ Reporter Cells, two optimized media for use during cell culture and (optionally) in diluting the test samples, a reference agonist, Luciferase Detection Reagent, a cell culture-ready assay plate, and a detailed protocol.


(From Aceview)

The gene contains 31 distinct gt-ag introns. Transcription produces 19 different mRNAs, 18 alternatively spliced variants and 1 unspliced form. There are 5 probable alternative promotors, 7 non overlapping alternative last exons and 8 validated alternative polyadenylation sites (see the diagram). The mRNAs appear to differ by truncation of the 5' end, truncation of the 3' end, presence or absence of 12 cassette exons, overlapping exons with different boundaries, splicing versus retention of one intron. 829 bp of this gene are antisense to spliced gene flaloyby, raising the possibility of regulated alternate expression. Note that mRNA .lAug10 was found in vivo, although it is a predicted target of nonsense mediated mRNA decay (NMD). Efficacy of translation may be reduced by the presence of a shorter translated product (uORF) initiating at an AUG upstream of the main open reading frame (in variant aAug10, cAug10, dAug10, eAug10). 




(From KEGG)

  • Ethinylestradiol
  • Estradiol
  • Estriol
  • Estrone
  • Promestriene
  • Conjugated estrogens
  • Dienestrol
  • Diethylstilbestrol
  • Tibolone
  • Clomifene
  • Raloxifene
  • Bazedoxifene
  • Lasofoxifene
  • Ormeloxifen
  • Ospemifene
  • Polyestradiol phosphate
  • Tamoxifen
  • Toremifene
  • Fulvestrant


(From BioGPS)